anti-inflammatoty and immuno-therapy living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 prophylaxis (excluding children)
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
neutralizing antibody
bamlanivimab monotherapy	BLAZE-2 US ...
casirivimab/imdevimab (Ronapreve)	Cov-2069 ...
cilgavimab and tixagevimab (Evusheld)	PROVENT

4930	Huijie Bian, 2020	2	31	3	excluded	not a RCT	high risk of bias
5317	Lu, 2020	1	22	3		not a RCT	high risk of bias
5319	Wu, 2020	1	13	3		not a RCT	high risk of bias
5453	Raef, 2020	1	13	4		not a RCT	high risk of bias
5454	Jianfeng, 2020	1	13	3		not a RCT	high risk of bias
5455	Tomasz, 2020	1	20	4		not a RCT	high risk of bias
5456	Fernández Cruz, 2020	1	13	3		not a RCT	high risk of bias
5476	Yuan, 2020	0	13	0	selection pending
5484	Salton (Methylprednisolone), 2020	0	13	4	selection pending
5485	openSafely, 2020	0	13	0	selection pending
5510	Malgorzata, 2020	1	13	4		not a RCT	high risk of bias
5552	Rahman, 2020	0	13	0	selection pending
5568	Zhang, 2020	0	13	0	selection pending
5603	Albani, 2020	0	13	0	selection pending
5612	Bernaola, 2020	2	13	0	excluded	not a RCT	risk of bias not avaialble
5614	Monreal, 2020	0	13	0	selection pending
5615	Nelson (Methylprednisolone), 2020	0	13	0	selection pending
5639	Li (Methylprednisolone, Shanghai cohort), 2020	0	13	0	selection pending
5796	SAM-COVID-19, 2020	0	13	0	selection pending
5840	Majmundar, 2020	0	13	0	selection pending
5939	Li (Methylprednisolone, Validation cohort), 2020	0	13	0	selection pending
5952	Rodriguez-Bano (intermediate-high dose CS), 2020	0	13	0	selection pending
5953	Rodriguez-Bano (CS pulse dose), 2020	0	13	0	selection pending
6036	Esba, 2020	0	10	0	selection pending
6048	Wu, 2020	0	11	0	selection pending